Back to News
Market Impact: 0.12
Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Eli Lilly reported 52-week results from the TOGETHER-PsO and TOGETHER-PsA studies evaluating the concomitant use of Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in adults with moderate-to-severe plaque psoriasis. The article does not provide efficacy/safety effect sizes, limiting immediate inference on incremental benefit beyond the 52-week dataset.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
LLY0.15
More News
- Here's our monthly update on our 32 stocks, including 2 more names to buy
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper